Indaptus Therapeutics, Inc., NASDAQ (INDP). www.idaptusrx.com. Chief Operating Officer and co-founder responsible for strategic decision-making, regulatory, compliance, general management, global operations, business development, investor relations, administration and oversight of innovative biopharmaceutical company. With the ability to harness both the body’s innate and adaptive immune responses, we believe we are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. Building on the observation that tumor regression can occur in the setting of bacterial infection, we have developed a proprietary biologic multi TLR agonist platform to activate both innate and adaptive cellular immune pathways. Leveraging our novel insights into the levels and ratios of activating signals needed to safely elicit a broad immune response, we are creating and advancing a pipeline of proprietary, attenuated and killed non-pathogenic Gram-negative bacterial candidates designed to be widely accessible, with broad anti-tumor and anti-viral activity.

Indaptus Therapeutics, Inc., NASDAQ (INDP). www.idaptusrx.com. Chief Business Officer and co-founder responsible for strategic decision-making, general management, global operations, business development, investor relations, administration and oversight of innovative biopharmaceutical company.

Founding executive member of Oxford Strategic Alliance, a multinational business development and referral enterprise for strategic advice, management and investment development/management for individuals and companies that are globalizing. Drawing upon the experience of seasoned multi-national professionals specifically trained in global business development, the Alliance helps companies and individuals in automotive, aviation, extractives, biotechnology, consumer products, medical device, pharmaceutical, information security, IT, oil and gas, metals production, energy and international finance obtain strategic advice and specialized consulting to advance their goals. Membership limited to graduates of Oxford University colleges and schools.

Membre du Conseil de Surveillance élu à compter du 27 octobre 2022. Accompagner et conseiller stratégiquement une société de biotechnologie innovante cotée sur EURONEXT. - Member of the Supervisory Board elected as of October 27, 2022. Provide strategic guidance and advice to innovative biotechnology company traded on EURONEXT.

Global Chief Business Officer responsible for strategic decision-making, general management, global operations, business development, investor relations, administration and oversight of innovative biopharmaceutical company publicly traded on NASDAQ. Intec Pharma developed pharmaceuticals with a unique delivery system called the Accordion Pill with the goal of improving the pharmacokinetics of human drugs that had either a narrow absorption window or poorly soluble drugs that belonged to Biopharmaceutics Classification System (BCS) class II and Class IV.

Development, investment in and management of early stage and mid-stage biotechnology companies developing treatments for unmet needs. Co-founder of pharmaceutical company focused on anti-viral development.

Responsible for strategic development, financial planning and cost control, business development, M&A, investor development, intellectual property creation/protection and all operational considerations of publicly traded biotech/pharma company focused on the development of novel anti-viral treatments for pandemic disease, hepatitis and other virus based disease using refined crystallography techniques with nucleoside and CRISPR-CAS9 approaches.

Strategic business counselor and attorney focused on assisting Life Science and developing technology companies with legal/regulatory compliance, licensing, acquisitions, business transactions and product development on a global basis.

Global General Counsel and Corporate Secretary responsible for the leadership and management of international departments providing legal and strategic advice, corporate security and corporate compliance for global medical device, dental device, healthcare IT and pharmaceutical company with $2.3 billion USD sales and manufacturing operations in 160 countries.

Managing Partner and founder of Atlanta Office, Chair of firm Life Science practice group. Responsible for the creation of office, development of market, hiring and supervision of all lawyers and staff. Direct P&L responsibility for firm, office and practice area. Developed international legal practice in the Life Sciences handling transactions, litigation and development of business strategy for global companies focused on the development and sales of pharmaceutical, biotechnology, medical device and human health products at all stages of development. Lead trial counsel on behalf of industry client successfully arguing a case of first impression that set limits of FDA regulatory authority in drug/device combination product regulation.

Board member and co-chair of state biotechnology economic development committee.

General Counsel and Corporate Secretary, responsible for law, government and public affairs functions of global branded pharmaceutical company. Developed strategy for development of company and successfully resolved complex legal/business issues in regulatory, litigation, transactional and intellectual property. Negotiated and completed numerous global M&A transactions and assisted with NDA approval and product launch of several drugs.

Business regulation and trade litigator, transactional and regulatory lawyer representing companies and individuals in the chemical, energy, aerospace, pharmaceutical, medical device and product services industries. (Associate 1990-98).

Earned commission as an Officer through Marine Corps Platoon Leader program upon graduation from Syracuse University and served with 7th Fleet WestPac and later under Commander Naval Air Force Atlantic, Naval Air Station, Brunswick. Promoted to Captain. Granted Top Secret security clearance. Special assignment responsibilities included command of composite security force unit tasked with anti-terrorist duties and sensitive national security matters. Implemented U.S. policy in protection of national security and conducted intelligence and threat assessments globally. Awarded three personal commendations by Commandant of the Marine Corps for professionalism and decorated by Secretary of the Navy for leadership and professionalism in the conduct of special classified security operations.